Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Ji Won Han, Heechul Nam, Pil Soo Sung, Sung Won Lee, Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
Clin Mol Hepatol 2025;31(2):509-524. Published online January 2, 2025
Background/Aims Hepatocellular carcinoma (HCC) exhibits significant sex disparities in incidence, yet its molecular mechanisms remain unclear. We explored the role of telomerase reverse transcriptase (TERT) genetic alterations and hepatitis B virus (HBV) integration, both known major contributors to HCC, in sex-specific risk for HBV-related HCC.
Methods We examined 310 HBV-related HCC tissues to investigate sex-specific TERT promoter (TERT-pro) mutations and HBV integration profiles, stratified by sex and age, and validated with single-cell RNA sequencing (scRNA-seq) data.
Results Tumors predominantly exhibited TERT-pro mutations (26.0% vs. 0%) and HBV-TERT integration (37.0% vs. 3.0%) compared to non-tumorous tissues. While TERT-pro mutations increased with age in both sexes, younger males (≤60 years) showed marked predominance compared to younger females. Males had significantly more HBV integrations at younger ages, while females initially had fewer integrations that gradually increased with age. Younger males' integrations showed significantly greater enrichment in the TERT locus compared to younger females, alongside a preference for promoters, PreS/S regions, and CpG islands. Overall, TERT genetic alterations were significantly sex-differential in younger individuals (75.3% in males vs. 23.1% in females) but not in older individuals (76.9% vs. 83.3%, respectively). These alterations were associated with increased TERT expression. The skewed TERT abnormalities in younger males were further corroborated by independent scRNA-seq data.
Conclusions Our findings highlight the critical role of TERT alterations and HBV integration patterns in the male predominance of HCC incidence among younger HBV carriers, offering insights for future exploration to optimize sex-specific patient care and HCC surveillance strategies.
Citations
Citations to this article as recorded by
Molecular biomarkers and nano-immunopharmacology in inflammatory carcinoma: Bridging mechanisms and therapeutic translation Kamlesh Sahu, Trilochan Satapathy, Poonam Sahu, Om Chandrakar Advances in Biomarker Sciences and Technology.2026; 8: 151. CrossRef
Mutational patterns and ancestry-linked profiles in a large hepatocellular carcinoma and combined hepatocellular–cholangiocarcinoma cohort C. Gerdes, S. Rengarajan, K. Murugesan, J.S. Ross, S. Bartels, A. Vogel, A. Saborowski ESMO Open.2026; 11(2): 106048. CrossRef
Shelterin Component TPP1 Drives Tumor Progression and Predicts Poor Prognosis in Hepatocellular Carcinoma Jung Eun Jang, Hye Seon Kim, Jin Seoub Kim, Jae Mo Han, Hee Sun Cho, Kwon Yong Tak, Ji Won Han, Pil Soo Sung, Si Hyun Bae, Jeong Won Jang Biomedicines.2026; 14(2): 364. CrossRef
Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications Jiayan Yan, Jiayi Wang, Jian Fan, Xinyi Cui, Yuxi Zhang, Xinrong Yang, Qiang Gao, Zhenbin Ding, Zhaoyou Tang, Jia Fan, Dan G. Duda, Ao Huang, Jian Zhou Portal Hypertension & Cirrhosis.2026; 5(1): 65. CrossRef
Digital polymerase chain reaction detection of telomerase reverse transcriptase promoter mutations in hepatitis B virus related hepatocellular carcinoma Shuai Shao, Yu Xiong, Mo-Wei Kong, Yang Yu, Chun-Xiang Zhang World Journal of Gastrointestinal Oncology.2026;[Epub] CrossRef
Clinicopathological significance of Gli1 expression in hepatocellular carcinoma: a meta-analysis Sisi Li, Mengfan Chen, Shanshan Zhang, Zhong Xu, Hongling Wang Scientific Reports.2026;[Epub] CrossRef
Letter to the editor on “Male preference for TERT alterations and HBV integration in young-age HBV-related HCC: implications for sex disparity” Qicong Mai, Jianming Zheng, Meishi Tang, Yubin Liu Clinical and Molecular Hepatology.2026; 32(2): e134. CrossRef
Functional cure for chronic hepatitis B on hepatocellular carcinoma prevention: Evidence and clinical implications Wen Kang, Yu-Shen Liu, Tian-Ping Wang, Shu-Ming Zhang, Yu Li, Ye Zhang iLIVER.2026; 5(2): 100235. CrossRef
Transcriptional regulation of tumor suppressor gene RASSF1A by HBx Yanhong Kang, Wei Li, Junfeng Wei, Lin Yang, Yi Kang Molecular and Cellular Probes.2025; 82: 102034. CrossRef
Optimized digital polymerase chain reaction enables detection of telomerase reverse transcriptase C228T mutation for prognostic assessment in hepatocellular carcinoma Zulihumaer Aizimuaji, Nan Hu, Hai-Yang Li, Xi-Jun Wang, Sheng Ma, Ya-Ru Wang, Rui-Qi Zheng, Zhuo Li, Huan Zhao, Wei-Qi Rong, Ting Xiao World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
Transjugular intrahepatic portosystemic shunt (TIPS) is an effective interventional procedure to relieve portal hypertension, which is a main mechanism for the development of complications of liver cirrhosis (LC), such as variceal hemorrhage, ascites, and hepatorenal syndrome. However, the high incidence of adverse events after TIPS implementation limits its application in clinical practice. Esophageal variceal hemorrhage is one of the major indications for TIPS. Recently, preemptively performed TIPS has been recommended, as several studies have shown that TIPS significantly reduced mortality as well as rebleeding or failure to control bleeding in patients who are at high risk of treatment failure for bleeding control with endoscopic variceal ligation and vasoactive drugs. Meanwhile, recurrent ascites is another indication for TIPS with a proven survival benefit. TIPS may also be considered as an effective treatment for other LC complications, usually as an alternative therapy. Although there are concerns about the development of hepatic encephalopathy and hepatic dysfunction after TIPS implementation, careful patient selection using prognostic scores can lead to excellent outcomes. Assessments of cardiac and renal function prior to TIPS may also be considered to improve patient prognosis.
Citations
Citations to this article as recorded by
Baseline Portal Vein Thrombosis does not Worsen Long-Term Outcomes After Technically Successful TIPS in Cirrhotic Variceal Bleeding: A Single-Center Retrospective Cohort Study Hongying Gan, Ting Jiang, Jiao Yu, Zhitao Song, Dan Zheng, Fan Wu CardioVascular and Interventional Radiology.2026;[Epub] CrossRef
Varices everywhere: Stomal bleeding due to undiagnosed portal hypertension Anastasia Crenshaw, Kaitlynn Borik, Joshua Julian, Tina H. Chen JEM Reports.2026; 5(1): 100203. CrossRef
Impact of quantitative dietary guidance on postoperative outcomes in patients undergoing transjugular intrahepatic portosystemic shunt surgery: a retrospective cohort study Yue Xu, Qin Yin, Jiangqiang Xiao, Qing Zhao, Xiaotian Chen, Ming Zhang, Bo Gao Frontiers in Nutrition.2026;[Epub] CrossRef
Timing of Transjugular Intrahepatic Portosystemic Shunts for Acute Esophagogastric Variceal Bleeding in Liver Cirrhosis Wentun Yao, Chunxiu Tan, Houqiang Su, Juan Xie, Liya Huang Hepatitis Monthly.2026;[Epub] CrossRef
Risk factors and predictive model for transjugular intrahepatic portosystemic shunt dysfunction in cirrhotic patients Yongbing Zhao, Tingwei Xiong, Sijie Hu, Hao Zhou, En Liu, Zhengguo Xu, Rui Xie European Journal of Gastroenterology & Hepatology.2026;[Epub] CrossRef
Evaluation of liver function and related factors in patients with chronic hepatitis B-related cirrhosis complicated with esophagogastric variceal bleeding Yue Feng, Bei Li, Yueyong Zhu, Biguang Tuo, Yiling Li, Die Huang, Lu Zhou, Yuhan Du, Hui Liu, Yu Dong, Ling Lan, Yuhan Lou, Shaoqi Yang, Weifang Ma, Chuan Zhang, Yutao Zhan Irish Journal of Medical Science (1971 -).2026;[Epub] CrossRef
Management of chylous ascites after liver cirrhosis: A case report Zong-Qiang Chen, Shu-Jun Zeng, Chun Xu World Journal of Hepatology.2025;[Epub] CrossRef
Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicenter Real‐World Study Yi Xiang, Jun Tie, Guangchuan Wang, Yuzheng Zhuge, Hao Wu, Xiaoli Zhu, Hui Xue, Shanghao Liu, Ling Yang, Jiao Xu, Feng Zhang, Mingyan Zhang, Bo Wei, Peijie Li, Ze Wang, Wei Wu, Chao Chen, Shifeng Yang, Yicheng Han, Chengwei Tang, Xiaolong Qi, Chunqing Zha Alimentary Pharmacology & Therapeutics.2025; 61(7): 1183. CrossRef
Effective Management of Refractory Hepatic Hydrothorax With Hypertonic Glucose Pleurodesis Shuya Hashimoto, Toyoshi Yanagihara, Natsumi Kushima, Rei Sanai, Takato Ikeda, Naoki Hamada, Masaki Fujita Cureus.2025;[Epub] CrossRef
Life-Saving Precision: Image-Guided Interventions Transforming Outcomes in Living-Donor Liver Transplant Complications Bribin Bright, Manish M Nair, Srikanth Moorthy, Sreekumar K P., Chinmay Kulkarni, Nazar P K. Cureus.2025;[Epub] CrossRef
Inferior vena cava-splenic vein shunt for the treatment of complete portal trunk occlusion and portal cavernoma in liver cirrhosis Maoyuan Mu, Yuzhe Cao, Zixiong Chen, Xiaobo Fu, Pengyi Chen, Han Qi, Fei Gao European Radiology.2025; 35(6): 3249. CrossRef
Application of 4D Flow MRI in Quantitative Evaluation of Portal Hypertension in Cirrhosis 琼 胡 Advances in Clinical Medicine.2025; 15(05): 287. CrossRef
Endovascular management of acute superior mesenteric vein thrombosis: a retrospective study on thrombolysis outcomes Nan Wei, René Michael Mathy, De-Hua Chang, Martin Loos, Uta Merle, Annika Gauss, Monica Boxberger, Philipp Mayer, Miriam Klauss, Hans-Ulrich Kauczor, Osman Öcal, Mark O. Wielpütz CVIR Endovascular.2025;[Epub] CrossRef
Investigation of bending angle algorithm and path planning for puncture needles in transjugular intrahepatic portosystemic shunt Qinmei Liao, Bing Li, Xihao Hu, Xiaoyun Huang, Jiacheng Guo, Yuanzhong Zhu, Wenjing He BioMedical Engineering OnLine.2025;[Epub] CrossRef
Recompensation after transjugular intrahepatic portosystemic shunt reduces mortality risk: A long-term follow-up study Yaowei Bai, Jiacheng Liu, Yu Lei, Bo Sun, Wenlong Wu, Xiatong Bai, Yang Su, Wei Tan, Xuefeng Kan, Chuansheng Zheng European Journal of Radiology.2025; 190: 112212. CrossRef
Transjugular Intrahepatic Portosystemic Shunt (TIPS): bridging the gap from bench to bedside Citra Indriani Sibarani, Karisma Septari Idamusaga, Amie Vidyani, Henry Sutanto Egyptian Liver Journal.2025;[Epub] CrossRef
Development of a deep learning model for guiding treatment decisions of acute variceal bleeding in patients with cirrhosis Yi Xiang, Na Yang, Tian-Lei Zheng, Yi-Fei Huang, Tian-Yu Liu, De-Qiang Ma, Sheng-Juan Hu, Wen-Hui Zhang, Hui-Ling Xiang, Li-Yao Zhang, Li-Li Yuan, Xing Wang, Tong Dang, Guo Zhang, Bin Wu, Li-Jun Peng, Min Gao, Dong-Li Xia, Zhen-Bei Liu, Jia Li, Ying Song, World Journal of Gastroenterology.2025;[Epub] CrossRef
A Case of Non-cirrhotic Portal Hypertension With Antiphospholipid Syndrome Mili Shah, Razia Gill, Priya Hotwani, Hamsika Moparty, Naresh Kumar, Dhir Gala, Vikash Kumar Cureus.2024;[Epub] CrossRef
Examining the therapeutic landscape of beta-blockers in portal hypertension Anna Brujats, Càndid Villanueva Clinical and Molecular Hepatology.2024; 30(4): 1055. CrossRef
Effectiveness and prognosis of covered stents with different diameters in transjugular intrahepatic portosystemic shunt: a meta-analysis Jiahong Gong, Ziqin Xia, Zhidai Zhou, Liping Chen, Xiaobing Wang, Feng Zhou European Journal of Gastroenterology & Hepatology.2024; 36(2): 229. CrossRef
Role of Portosystemic Shunt and Portal Vein Stent in Managing Portal Hypertension Due to Hematological Diseases Ji Hoon Kim, Suho Kim, Hee-Chul Nam, Chang Wook Kim, Jae-Sung Yoo, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Ho-Jong Chun, Sung-Eun Lee, Jung-Suk Oh, Pil Soo Sung Cureus.2024;[Epub] CrossRef
Development of a new Cox model for predicting long-term survival in hepatitis cirrhosis patients underwent transjugular intrahepatic portosystemic shunts Yi-Fan Lv, Bing Zhu, Ming-Ming Meng, Yi-Fan Wu, Cheng-Bin Dong, Yu Zhang, Bo-Wen Liu, Shao-Li You, Sa Lv, Yong-Ping Yang, Fu-Quan Liu World Journal of Gastrointestinal Surgery.2024; 16(2): 491. CrossRef
Efficacy of transjugular intrahepatic portosystemic shunts in treating cirrhotic esophageal-gastric variceal bleeding Xiao-Gang Hu, Jian-Ji Dai, Jun Lu, Gang Li, Jia-Min Wang, Yi Deng, Rui Feng, Kai-Ping Lu World Journal of Gastrointestinal Surgery.2024; 16(2): 471. CrossRef
Radiological and Surgical Treatments of Portal Hypertension Charlotte Hunt, Mausam Patel, Maria del Pilar Bayona Molano, Madhukar S. Patel, Lisa B. VanWagner Clinics in Liver Disease.2024; 28(3): 437. CrossRef
Indicaciones, contraindicaciones y técnica de la derivación percutánea portosistémica percutánea transyugular J.S. Cea Rama, D. Villaescusa Arenas, E. Tavio, J. Urbano, L. Téllez Villajos Medicine - Programa de Formación Médica Continuada Acreditado.2024; 14(10): 591. CrossRef
Utilizing a suture-constrained covered stent for shunt reduction to treat transjugular intrahepatic portosystemic shunt-related refractory hepatic encephalopathy: a retrospective study Maoyuan Mu, Tengchao Zhou, Huanqing Guo, Xiaobo Fu, Zixiong Chen, Weiwei Jiang, Lixue Li, Han Qi, Fei Gao Japanese Journal of Radiology.2024; 42(11): 1298. CrossRef
Chinese guidelines on the management of ascites in cirrhosis Xiaoyuan Xu, Huiguo Ding, Jidong Jia, Lai Wei, Zhongping Duan, Chengwei Tang, Enqiang Linghu, Yuemin Nan, Ying Han, Jinghang Xu, Hui Zhuang Hepatology International.2024; 18(4): 1071. CrossRef
The Role of the Transjugular Intrahepatic Porto-Systemic Shunt in an Emergency Setting Alessandro Posa, Lorenzo Tenore, Pierluigi Barbieri, Giulia Mazza, Evis Sala, Roberto Iezzi Life.2023; 13(4): 868. CrossRef
Contributory roles of sarcopenia and myosteatosis in development of overt hepatic encephalopathy and mortality after transjugular intrahepatic portosystemic shunt Liang Yin, Sen-Lin Chu, Wei-Fu Lv, Chun-Ze Zhou, Kai-Cai Liu, Yi-Jiang Zhu, Wen-Yue Zhang, Cui-Xia Wang, Yong-Hui Zhang, Dong Lu, De-Lei Cheng World Journal of Gastroenterology.2023; 29(18): 2875. CrossRef
Transjugular intrahepatic portosystemic shunt for pyrrolidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective cohort study Tongmin Huang, Xingfen Zhang, Kun Yan, Dandi Lou, Yujing He, Senjie Dai, Dingcheng Zheng, Ping Chen, Feng Wu, Lihu Gu European Journal of Gastroenterology & Hepatology.2023; 35(9): 1004. CrossRef
How to suspect the presence of high‐risk esophageal varices and when to start endoscopic surveillance in children with biliary atresia? Ujjal Poddar, Arghya Samanta, Moinak Sen Sarma, Basant Kumar, Richa Lal, Anshu Srivastava, Vijay Datta Upadhyaya, Surender Kumar Yachha, Ankur Mandelia Journal of Gastroenterology and Hepatology.2023; 38(9): 1610. CrossRef
Research Progress on Risk Factors of Hepatic Encephalopathy after TIPS 倩倩 何 Advances in Clinical Medicine.2023; 13(10): 15870. CrossRef
How to manage a patient with chronic liver disease undergoing colorectal surgery? Benoît Dupont, Arnaud Alves Seminars in Colon and Rectal Surgery.2023; 34(4): 100986. CrossRef
Impressive recompensation in transjugular intrahepatic portosystemic shunt-treated individuals with complications of decompensated cirrhosis based on Baveno VII criteria Long Gao, Man-Biao Li, Jin-Yu Li, Yang Liu, Chao Ren, Dui-Ping Feng World Journal of Gastroenterology.2023; 29(38): 5383. CrossRef
Risks and benefits of TIPS in HCC and other liver malignancies: a literature review Anna Fichtl, Thomas Seufferlein, Eugen Zizer BMC Gastroenterology.2023;[Epub] CrossRef
Pulmonary Complications in Patients with Liver Cirrhosis Seul Ki Han, Soon Koo Baik, Moon Young Kim The Korean Journal of Gastroenterology.2023; 82(5): 213. CrossRef
Noncirrhotic portal hypertension due to peripheral T-cell lymphoma, not otherwise specified: A case report Miao-Miao Wu, Wen-Jun Fu, Jia Wu, Lin-Lin Zhu, Ting Niu, Rong Yang, Jin Yao, Qiang Lu, Xiao-Yang Liao World Journal of Clinical Cases.2022; 10(26): 9417. CrossRef
Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediateterm efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.
Citations
Citations to this article as recorded by
Urgent need for education on hepatocellular carcinoma surveillance among high-risk population in China Lei Cai, Chao Li, Li-Yang Sun, Yong-Kang Diao, Ming-Da Wang, Tian Yang Clinical and Molecular Hepatology.2025; 31(1): e39. CrossRef
Comparison of tenofovir versus entecavir for preventing hepatocellular carcinoma in chronic hepatitis B patients: an umbrella review and meta-analysis Shi-Jia Liu, Xiao Zhang, Lun-Jie Yan, Han-Chao Wang, Zi-Niu Ding, Hui Liu, Guo-Qiang Pan, Cheng-Long Han, Bao-Wen Tian, Zhao-Ru Dong, Dong-Xu Wang, Yu-Chuan Yan, Tao Li Journal of Cancer Research and Clinical Oncology.2025;[Epub] CrossRef
Comparative risk of osteoporosis and fractures in chronic hepatitis B patients: Tenofovir disoproxil fumarate vs. entecavir in a Korean nationwide cohort Yoon E. Shin, Jae Young Kim, Hyuk Kim, Jeong Ju Yoo, Sang Gyune Kim, Young Seok Kim JHEP Reports.2025; 7(9): 101489. CrossRef
Drug Repurposing for Kala-Azar Biljana Arsić, Budimir S. Ilić, Andreas Maier, Michael Hartung, Jovana Janjić, Jelena Milićević, Jan Baumbach Pharmaceutics.2025; 17(8): 1021. CrossRef
Tenofovir disoproxil fumarate: safe and effective option for managing high-viral-load chronic hepatitis B Wenyuan Song American Journal of Translational Research.2025; 17(4): 3228. CrossRef
Enhanced Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma Using Age-male-albumin-bilirubin-platelet (aMAP) and Liver Stiffness Assessed by Vibration-controlled Transient Elastography Hye Yeon Chon, Hyung Joon Yim, Seok-Jae Heo, Su Jong Yu, Ja Kyung Kim, Sang Hoon Ahn, Grace Lai-Hung Wong, Jimmy Che-To Lai, Terry Cheuk-Fung Yip, Sang Gyune Kim, Yeon Seok Seo, Seung Up Kim Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
MDSC-targeted liposomal all-trans retinoic acid suppresses mMdscs and improves immunotherapy in HBV infection Samuel Kesse, Yuhong Xu, Sanyuan Shi, Shanshan Jin, Shafi Ullah, Yongchao Dai, Miao He, Anjie Zheng, Fengwei Xu, Zixiu Du, Raphael N. Alolga, Jinliang Peng Expert Opinion on Drug Delivery.2024; 21(2): 347. CrossRef
Development and Validation of a Machine Learning-Based Model Used for Predicting Hepatocellular Carcinoma Risk in Patients with Hepatitis B-Related Cirrhosis: A Retrospective Study Yixin Hou, Jianguo Yan, Ke Shi, Xiaoli Liu, Fangyuan Gao, Tong Wu, Peipei Meng, Min Zhang, Yuyong Jiang, Xianbo Wang OncoTargets and Therapy.2024; Volume 17: 215. CrossRef
Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, Mi-Sook Kim, Jeayeon Park, Hyunjae Shin, Sung Won Chung, Hee Jin Cho, Min Kyung Park, Heejoon Jang, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yong Jin Jung, Yoon Jun Kim, Jung-Hwan Yoon Clinical and Molecular Hepatology.2024; 30(3): 500. CrossRef
Nucleos(t)ide analog therapy of chronic hepatitis B and extrahepatic cancer risk: Is tenofovir better than entecavir?: Editorial on “Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study” Yewan Park, Dong Hyun Sinn Clinical and Molecular Hepatology.2024; 30(4): 718. CrossRef
Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim European Journal of Internal Medicine.2023; 107: 66. CrossRef
Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: A systematic review and meta‐analysis Suprabhat Giri, Dhiraj Agrawal, Shivaraj Afzalpurkar, Amrit Gopan, Sumaswi Angadi, Sridhar Sundaram Journal of Viral Hepatitis.2023; 30(2): 108. CrossRef
Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim American Journal of Gastroenterology.2023; 118(6): 1001. CrossRef
ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Se Young Jang, Won Young Tak, Young-Oh Kweon, Soo Young Park, Seung Up Kim Clinical Gastroenterology and Hepatology.2023; 21(9): 2278. CrossRef
Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim European Journal of Clinical Investigation.2023;[Epub] CrossRef
Lower risk of hepatocellular carcinoma with tenofovir than entecavir in antiviral treatment-naïve chronic hepatitis B patients: a systematic review and meta-analysis involving 90,897 participants Jinman Shao, Yishu Wang, Ling Hu, Lianchao Zhang, Chunmei Lyu Clinical and Experimental Medicine.2023; 23(6): 2131. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi, Hepatology.2023; 77(5): 1746. CrossRef
Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis Hui Liu, Cheng-Long Han, Bao-Wen Tian, Zi-Niu Ding, Ya-Fei Yang, Yun-Long Ma, Chun-Cheng Yang, Guang-Xiao Meng, Jun-Shuai Xue, Dong-Xu Wang, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li Expert Review of Gastroenterology & Hepatology.2023; 17(6): 623. CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy Beom Kyung Kim, Sang Hoon Ahn Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B Hye Won Lee, Hwiyoung Kim, Taeyun Park, Soo Young Park, Young Eun Chon, Yeon Seok Seo, Jae Seung Lee, Jun Yong park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim Liver International.2023; 43(8): 1813. CrossRef
Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma Sang Hyun Seo, Kyung Joo Cho, Hye Jung Park, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jae Hee Cheon, Jong In Yook, Man-Deuk Kim, Dong Jin Joo, Seung Up Kim Cell Communication and Signaling.2023;[Epub] CrossRef
Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta‐analysis Bao‐Hong Yuan, Ru‐Hong Li, Rong‐Rui Huo, Min‐Jun Li, George Papatheodoridis, Jian‐Hong Zhong Journal of Gastroenterology and Hepatology.2022; 37(5): 782. CrossRef
Comparable Efficacy Between Ongoing Versus Initiation of Antiviral Therapy at Treatment for HBV-related Hepatocellular Carcinoma Mi Na Kim, Beom Kyung Kim, Yun Ho Roh, Na Ryung Choi, Su Jong Yu, Seung Up Kim Clinical Gastroenterology and Hepatology.2022; 20(8): 1877. CrossRef
A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients Hyung Joon Kim, Ju Hyun Kim, Jong Eun Yeon, Yeon Seok Seo, Jeong Won Jang, Yong Kyun Cho, Byoung Kuk Jang, Byung Hoon Han, Changhyeong Lee, Joon Hyeok Lee, Jung-Hwan Yoon, Kang Mo Kim, Moon Young Kim, Do Young Kim, Neung Hwa Park, Eun Young Cho, June Sung Journal of Korean Medical Science.2022;[Epub] CrossRef
Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts Sang Il Choi, Yuri Cho, Moran Ki, Bo Hyun Kim, In Joon Lee, Tae Hyun Kim, Seong Hoon Kim, Young Hwan Koh, Hyun Beom Kim, Eun Kyung Hong, Chang-Min Kim, Joong-Won Park, Hamidreza Karimi-Sari PLOS ONE.2022; 17(3): e0265668. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, Jin-Woo Lee Clinical and Molecular Hepatology.2022; 28(3): 351. CrossRef
Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim European Journal of Internal Medicine.2022; 103: 122. CrossRef
Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database Hankil Lee, Beom Kyung Kim Journal of Gastroenterology and Hepatology.2022; 37(11): 2154. CrossRef
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim Hepatology Research.2022; 52(12): 975. CrossRef
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Korean Journal of Radiology.2022; 23(12): 1126. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim Diagnostics.2022; 13(1): 3. CrossRef
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients Hye Yeon Chon, Sang Hoon Ahn, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Dong Hyun Sinn, Seung Up Kim Hepatology International.2021; 15(6): 1328. CrossRef
Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir Jung Hyun Lim, Jung Hwan Yu, Young Ju Suh, Jin-Woo Lee, Young-Joo Jin Medicine.2021; 100(39): e27417. CrossRef
Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2021; 13(23): 5892. CrossRef
The association between hepatocarcinogenesis and intracellular alterations due to hepatitis B virus infection Masataka Tsuge Liver International.2021; 41(12): 2836. CrossRef
Hyun Yang, Hyun Young Woo, Soon Kyu Lee, Ji Won Han, Bohyun Jang, Hee Chul Nam, Hae Lim Lee, Sung Won Lee, Do Seon Song, Myeong Jun Song, Jung Suk Oh, Ho Jong Chun, Jeong Won Jang, Angelo Lozada, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Clin Mol Hepatol 2017;23(2):128-137. Published online May 10, 2017
Background/Aims Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).
Methods A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS.
Results The median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (≥400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008).
Conclusions MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.
Citations
Citations to this article as recorded by
Hepatic arterial infusion chemotherapy (HAlC) versus sorafenib for hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) B/C: A systematic review and meta-analysis Zhengqiang Chen, Yaotian Fan, Yuting Luo, Xiwen Ye, Zhen You, Do Young Kim PLOS One.2026; 21(2): e0342495. CrossRef
Optimal candidates and surrogate endpoints for HAIC versus Sorafenib in hepatocellular carcinoma: an updated systematic review and meta-analysis Tengfei Si, Qing Shao, Wayel Jassem, Yun Ma, Nigel Heaton International Journal of Surgery.2025; 111(1): 1203. CrossRef
The deubiquitinating enzyme ATXN3 promotes hepatocellular carcinoma progression by stabilizing TAZ Yuanhao Peng, Hui Nie, Kuo Kang, Xuanxuan Li, Yongguang Tao, Yangying Zhou Cancer Gene Therapy.2025; 32(1): 136. CrossRef
Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis Shun-An Zhou, Qing-Mei Zhou, Lei Wu, Zhi-Hong Chen, Fan Wu, Zhen-Rong Chen, Lian-Qun Xu, Bi-Ling Gan, Hao-Sheng Jin, Ning Shi World Journal of Gastrointestinal Oncology.2024; 16(8): 3672. CrossRef
Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis Nandini Gupta, Neelkant Verma, Bhoomika Patel Journal of Gastrointestinal Cancer.2024; 55(4): 1485. CrossRef
Clinical significance of exosomal noncoding RNAs in hepatocellular carcinoma: a narrative review Jae Sung Yoo, Min Kyu Kang Journal of Yeungnam Medical Science.2024; 42: 4. CrossRef
Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review Wei Zhang, Deliang Ouyang, Zhangkan Huang, Xu Che Frontiers in Oncology.2023;[Epub] CrossRef
Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review Zi-Wen Tao, Bao-Quan Cheng, Tao Zhou, Yan-Jing Gao Hepatobiliary & Pancreatic Diseases International.2022; 21(2): 134. CrossRef
A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study Juxian Sun, Chang Liu, Jie Shi, Nanya Wang, Dafeng Jiang, Feifei Mao, Jingwen Gu, Liping Zhou, Li Shen, Wan Yee Lau, Shuqun Cheng Chinese Medical Journal.2022; 135(19): 2338. CrossRef
Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study Dong Hyun Sinn, Hye Won Lee, Yong-Han Paik, Do Young Kim, Yoon Jun Kim, Kang Mo Kim, Si Hyun Bae, Ji Hoon Kim, Yeon Seok Seo, Jae Young Jang, Byoung Kuk Jang, Hyung Joon Yim, Hyung Joon Kim, Byung Seok Lee, Bo Hyun Kim, In Hee Kim, Eun-Young Cho, Jung Il Digestive Diseases and Sciences.2021; 66(1): 315. CrossRef
Survival in untreated hepatocellular carcinoma: A national cohort study Young Ae Kim, Danbee Kang, Hyeyoung Moon, Donghyun Sinn, Minwoong Kang, Sang Myung Woo, Yoon Jung Chang, Boram Park, Sun-Young Kong, Eliseo Guallar, Soo-Yong Shin, Geunyeon Gwak, Joung Hwan Back, Eun Sook Lee, Juhee Cho, Gianfranco D. Alpini PLOS ONE.2021; 16(2): e0246143. CrossRef
Capecitabine Treatment: A Safe and Effective Therapy in the Field of Oncology Linda Beenet Clinical Colorectal Cancer.2021; 20(3): e194. CrossRef
Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments Hiroyuki Suzuki, Hideki Iwamoto, Masahito Nakano, Toru Nakamura, Atsutaka Masuda, Takahiko Sakaue, Toshimitsu Tanaka, Dan Nakano, Ryoko Kuromatsu, Takashi Niizeki, Shusuke Okamura, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Hirohisa Yano, A Translational Oncology.2021; 14(11): 101201. CrossRef
The Role of Hepatic Arterial Infusion Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Shengzhou Li, Jiaxuan Xu, Hongya Zhang, Jiaze Hong, Yuexiu Si, Tong Yang, Yujing He, Derry Minyao Ng, Dingcheng Zheng Chemotherapy.2021; 66(4): 124. CrossRef
Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis Miao Liu, Junyi Shi, Tong Mou, Yang Wang, Zhongjun Wu, Ai Shen Journal of Gastroenterology and Hepatology.2020; 35(8): 1277. CrossRef
Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy Pil Soo Sung, Moon Hyung Choi, Hyun Yang, Soon Kyu Lee, Ho Jong Chun, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Joon-Il Choi, Young Joon Lee, Si Hyun Bae Frontiers in Oncology.2020;[Epub] CrossRef
ASPP2 enhances chemotherapeutic sensitivity through the down-regulation of XIAP expression in a p53 independent manner in hepatocellular carcinoma Tongwang Yang, Yuxue Gao, Daojie Liu, Yang Wang, Jing Wu, Xiaoni Liu, Ying Shi, Dexi Chen Biochemical and Biophysical Research Communications.2019; 508(3): 769. CrossRef
Selective embolization with magnetized microbeads using magnetic resonance navigation in a controlled‐flow liver model François Michaud, Ning Li, Rosalie Plantefève, Zeynab Nosrati, Charles Tremblay, Katayoun Saatchi, Gerald Moran, Alexandre Bigot, Urs O. Häfeli, Samuel Kadoury, An Tang, Pierre Perreault, Sylvain Martel, Gilles Soulez Medical Physics.2019; 46(2): 789. CrossRef
Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience Cem Simsek, Ece Esin, Suayib Yalcin Journal of Oncology.2019; 2019: 1. CrossRef
Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis Bo-wen Zhuang, Wei Li, Xiao-hua Xie, Hang-tong Hu, Ming-de Lu, Xiao-yan Xie Japanese Journal of Clinical Oncology.2019; 49(9): 845. CrossRef
Sorafenib-loaded hydroxyethyl starch-TG100-115 micelles for the treatment of liver cancer based on synergistic treatment Guofei Li, Limei Zhao Drug Delivery.2019; 26(1): 756. CrossRef
Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers Lucia Cerrito, Brigida Eleonora Annicchiarico, Roberto Iezzi, Antonio Gasbarrini, Maurizio Pompili, Francesca Romana Ponziani World Journal of Gastroenterology.2019; 25(31): 4360. CrossRef
Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma Min Kyu Kang, Jung Gil Park, Heon Ju Lee Medicine.2018; 97(17): e0611. CrossRef
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis Jong Hwan Choi, Woo Jin Chung, Si Hyun Bae, Do Seon Song, Myeong Jun Song, Young Seok Kim, Hyung Joon Yim, Young Kul Jung, Sang Jun Suh, Jun Yong Park, Do Young Kim, Seung Up Kim, Sung Bum Cho Cancer Chemotherapy and Pharmacology.2018; 82(3): 469. CrossRef
Rationale for the use of metronomic chemotherapy in gastrointestinal cancer Roberto Filippi, Pasquale Lombardi, Ilaria Depetris, Elisabetta Fenocchio, Virginia Quarà, Giovanna Chilà, Massimo Aglietta, Francesco Leone Expert Opinion on Pharmacotherapy.2018; 19(13): 1451. CrossRef
Liver‑targeted delivery of liposome‑encapsulated curcumol using galactosylated‑stearate Wen‑Jie Li, You‑Wen Lian, Quan‑Sheng Guan, Ning Li, Wen‑Jun Liang, Wen‑Xin Liu, Yong‑Bin Huang, Yi Cheng, Hui Luo Experimental and Therapeutic Medicine.2018;[Epub] CrossRef
Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma? Do Young Kim Clinical and Molecular Hepatology.2017; 23(2): 123. CrossRef
First
Prev
